Ambrx Biopharma Management
Management criteria checks 1/4
Ambrx Biopharma's CEO is Dan O'Connor, appointed in Nov 2022, has a tenure of 1.33 years. total yearly compensation is $1.03M, comprised of 6.7% salary and 93.3% bonuses, including company stock and options. directly owns 0.076% of the company’s shares, worth $1.35M. The average tenure of the management team and the board of directors is 1.1 years and 1.5 years respectively.
Key information
Dan O'Connor
Chief executive officer
US$1.0m
Total compensation
| CEO salary percentage | 6.7% |
| CEO tenure | 1.3yrs |
| CEO ownership | 0.08% |
| Management average tenure | 1.1yrs |
| Board average tenure | 1.5yrs |
Recent management updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2023 | n/a | n/a | -US$67m |
| Jun 30 2023 | n/a | n/a | -US$60m |
| Mar 31 2023 | n/a | n/a | -US$71m |
| Dec 31 2022 | US$1m | US$69k | -US$78m |
Compensation vs Market: Dan's total compensation ($USD1.03M) is below average for companies of similar size in the US market ($USD4.96M).
Compensation vs Earnings: Insufficient data to compare Dan's compensation with company performance.
CEO
Dan O'Connor (58 yo)
1.3yrs
Tenure
US$1,034,168
Compensation
Mr. Daniel J. O'Connor, J.D., also known as Dan, served as an Independent Director of ZyVersa Therapeutics, Inc. since December 13, 2022 until May 2023. He serves as President, CEO and Director of Ambrx Bi...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 1.3yrs | US$1.03m | 0.076% $ 1.3m | |
| Chief Financial Officer | 2.8yrs | US$1.73m | 0.036% $ 641.7k | |
| Chief Operating Officer | less than a year | no data | 0% $ 0 | |
| Chief Technology Officer | 2.2yrs | no data | no data | |
| Chief Scientific Officer & GM of China | 1.4yrs | no data | no data | |
| Senior VP | less than a year | no data | no data | |
| Vice President of Human Capital | less than a year | no data | no data | |
| Chief Clinical Officer | 1.1yrs | no data | no data | |
| Chief Regulatory Officer | less than a year | no data | no data |
1.1yrs
Average Tenure
55yo
Average Age
Experienced Management: AMAM's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 1.3yrs | US$1.03m | 0.076% $ 1.3m | |
| Independent Director | 2.1yrs | US$268.55k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Director | less than a year | no data | no data | |
| Chairman of the Board | less than a year | no data | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 1.7yrs | US$555.41k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 1.8yrs | US$156.12k | 0% $ 0 |
1.5yrs
Average Tenure
59yo
Average Age
Experienced Board: AMAM's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.